Starpharma Holdings (ASX:SPL) Shares Drift As Revenue More Than Doubles

Starpharma Holdings closed at A$0.715 on Thursday after a soft week for the stock, yet the fresh full year numbers tell a more complicated story than the share price alone suggests. The headline is simple. A small A$1.5 million revenue base in the second half has been swallowed by a much larger net loss, which keeps the company firmly in loss making territory for now.

The key consideration for you as an investor is time horizon. Today the market is reacting to red ink. Over the next few years the focus may shift to whether the existing growth forecasts and premium P/S multiple are supported by actual cash generation.

Love the Starpharma Holdings story but worried about a small revenue base alongside ongoing losses? You can compare it with stocks that pair growth potential with stronger balance sheets in our list of solid balance sheet and fundamentals stocks (22 results).

FY 2026 Earnings Summary

• Revenue FY 2026: A$12.7 million (trailing twelve months to 2H FY 2026) vs. A$5.9 million for the prior 12 month period to 2H FY 2025 (very large increase, more than 2x).
• Net Loss FY 2026: A$7.5 million loss (trailing twelve months to 2H FY 2026) vs. A$10.0 million loss for the prior 12 month period to 2H FY 2025 (loss narrowed by 25.3%).
• Basic EPS FY 2026: A$0.02 loss per share (trailing twelve months to 2H FY 2026) vs. A$0.02 loss per share for the prior 12 month period to 2H FY 2025 (small improvement from a slightly larger loss).
• Earnings from Continuing Operations FY 2026: A$7.5 million loss (trailing twelve months to 2H FY 2026) vs. A$10.0 million loss for the prior 12 month period to 2H FY 2025 (loss narrowed by 25.3%).

Prefer clean visuals to staring at rows of figures and dense earnings notes on Starpharma Holdings? View a clear overview of its revenue and earnings profile in a simple visual format with our company report for Starpharma Holdings.

Starpharma revenue traction supports selective optimism

For bullish investors, the latest figures from Starpharma show a business that is at least moving in the right direction on core economics. Revenue for the trailing twelve months to 2H FY 2026 is A$12.7 million compared with A$5.9 million a year earlier, which supports the idea that commercial products and partnerships are contributing more meaningfully. The net loss narrowed to A$7.5 million from A$10.0 million. That trend fits a thesis that the platform is gaining commercial footholds, even if it is still early stage and far from self funding.

Losses and share pullback keep bear case alive

The bearish story around Starpharma still has plenty to work with. The company remains firmly loss making with a A$7.5 million net loss over the last twelve months, and basic EPS is still a A$0.02 loss per share. Recent share price performance has been soft, with the stock down about 6% over seven days and 4% over thirty days. Those moves suggest investors remain cautious about the pace at which revenue can cover ongoing development costs, even though the loss has narrowed year on year.

Compare Starpharma Holdings' narrowing loss and revenue traction with how the stock actually trades around A$0.715 today, then see whether analysts think this earnings reset is the start of a real rerating or just a pause before lower expectations by checking the consensus price target analysis for Starpharma Holdings.

Stay Ahead With Simply Wall St

If the recent mix of revenue traction and ongoing losses at Starpharma Holdings has your attention, register for free with Simply Wall St and add the stock to a Watchlist so you can track its share price against fair value and watch how the story develops. When you decide to take a position, keep your next moves clear and focused with the Portfolio Command Center that highlights only the most important developments across your holdings. For a broader view on what other investors are thinking, use the Community to compare different perspectives and surface questions you might not have considered. By spotting potential catalysts and risks early, you may be able to stay more prepared for market developments rather than reacting to them.

Seeking Alternatives Beyond Starpharma Holdings

Fresh ideas do not stay under the radar for long. Spot breakout momentum and stocks quietly building strength before the crowd catches on. The window is moving, act now.

• Spot resilient businesses where cash flow and balance sheets already do the heavy lifting by scanning our curated list of solid balance sheet and fundamentals stocks (22 results) while the market focus is still elsewhere.
• Target steady income streams that can offset volatility by checking companies in the hand picked 8 dividend fortresses before yields get compressed by fresh buying momentum.
• Hunt for under the radar compounders by reviewing carefully filtered 12 high quality undiscovered gems while they are still quietly building traction and before expectations start flying.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com